PL1638937T3 - Krystaliczna postać XIV soli sodowej fluwastatyny, sposoby jej wytwarzania, kompozycje farmaceutyczne zawierające tę postać oraz sposoby ich stosowania - Google Patents

Krystaliczna postać XIV soli sodowej fluwastatyny, sposoby jej wytwarzania, kompozycje farmaceutyczne zawierające tę postać oraz sposoby ich stosowania

Info

Publication number
PL1638937T3
PL1638937T3 PL04755797T PL04755797T PL1638937T3 PL 1638937 T3 PL1638937 T3 PL 1638937T3 PL 04755797 T PL04755797 T PL 04755797T PL 04755797 T PL04755797 T PL 04755797T PL 1638937 T3 PL1638937 T3 PL 1638937T3
Authority
PL
Poland
Prior art keywords
processes
preparing
methods
compositions containing
crystal form
Prior art date
Application number
PL04755797T
Other languages
English (en)
Inventor
Revital Lifshitz-Liron
Tamas Koltai
Judith Aronhime
Nurit Perlman
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of PL1638937T3 publication Critical patent/PL1638937T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL04755797T 2003-06-18 2004-06-18 Krystaliczna postać XIV soli sodowej fluwastatyny, sposoby jej wytwarzania, kompozycje farmaceutyczne zawierające tę postać oraz sposoby ich stosowania PL1638937T3 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US47918203P 2003-06-18 2003-06-18
US48309903P 2003-06-30 2003-06-30
US48574803P 2003-07-10 2003-07-10
US49379303P 2003-08-11 2003-08-11
US50795403P 2003-10-03 2003-10-03
US54546604P 2004-02-19 2004-02-19
EP04755797A EP1638937B1 (en) 2003-06-18 2004-06-18 Fluvastatin sodium crystal form xiv, processes for preparing it, compositions containing it and methods of using it
PCT/US2004/019879 WO2004113291A2 (en) 2003-06-18 2004-06-18 Fluvastatin sodium crystal forms xiv, lxxiii,lxxix, lxxx and lxxxvii, processes for preparing them, compositions containing them and methods of using them

Publications (1)

Publication Number Publication Date
PL1638937T3 true PL1638937T3 (pl) 2009-06-30

Family

ID=33545688

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04755797T PL1638937T3 (pl) 2003-06-18 2004-06-18 Krystaliczna postać XIV soli sodowej fluwastatyny, sposoby jej wytwarzania, kompozycje farmaceutyczne zawierające tę postać oraz sposoby ich stosowania

Country Status (14)

Country Link
US (4) US7414140B2 (pl)
EP (9) EP1726583A3 (pl)
JP (3) JP4037898B2 (pl)
KR (6) KR20070092993A (pl)
CN (1) CN1849304A (pl)
AT (1) ATE417827T1 (pl)
CA (6) CA2613021A1 (pl)
DE (1) DE602004018494D1 (pl)
ES (1) ES2317012T3 (pl)
IL (2) IL172512A0 (pl)
MX (2) MXPA05013895A (pl)
PL (1) PL1638937T3 (pl)
PT (1) PT1638937E (pl)
WO (2) WO2004113291A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200510414A (en) * 2003-06-02 2005-03-16 Teva Pharma Novel crystalline forms of valacyclovir hydrochloride
US7368581B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
PT1638937E (pt) * 2003-06-18 2009-01-27 Teva Pharma Forma xiv cristalina de fluvastatina sódica, processos para a sua preparação, composições que a contêm e métodos de utilização
WO2005037787A1 (en) * 2003-10-16 2005-04-28 Ciba Specialty Chemicals Holding Inc. Crystalline form of fluvastatin sodium
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
WO2005080332A1 (en) * 2004-01-14 2005-09-01 Cadila Healthcare Limited Novel form of fluvastatin sodium
WO2006030304A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
JP2008515878A (ja) * 2004-10-05 2008-05-15 バイオコン・リミテッド アモルファス型フルバスタチンナトリウムの製造方法
US7795451B2 (en) * 2005-02-11 2010-09-14 Jubilant Organosys Limited Polymorphic forms of fluvastatin sodium and process for preparing the same
AU2005329625A1 (en) * 2005-03-22 2006-09-28 Usv Limited Novel polymorph Form G of Fluvastatin sodium and process for the preparation thereof
WO2006109147A1 (en) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
TW200804279A (en) * 2006-02-27 2008-01-16 Teva Pharma Fluvastatin sodium novel forms and preparation thereof
DE602006006899D1 (de) 2006-04-20 2009-07-02 Italiana Sint Spa Verfahren zur Herstellung von Fluvastatin-Natrium
US20110052688A1 (en) * 2006-11-21 2011-03-03 San-Laung Chow Solid dispersion composition
ES2321571B1 (es) * 2007-07-18 2010-03-11 Ercros Industrial, S.A. Solvatos de fluvastatina sodica y su utilizacion como intermedios en la obtencion de fluvastatina sodica amorfa.
CN101250153B (zh) * 2008-02-26 2013-09-18 深圳信立泰药业股份有限公司 一种制备氟伐他汀钠晶型的工艺
PT2419407E (pt) * 2009-04-15 2013-01-28 Pharmathen Sa Processo melhorado para a preparação de fluvastatina e dos seus sais
WO2011117875A1 (en) * 2010-03-26 2011-09-29 Hetero Research Foundation Salts of fluvastatin and process for the preparation of substantially amorphous fluvastatin sodium
KR101220266B1 (ko) * 2012-04-19 2013-01-09 홍종옥 수치지도 이미지 제작을 위한 항공영상 이미지 기반 정밀 영상도화 시스템
KR101308745B1 (ko) * 2012-07-04 2013-09-16 주식회사 동운 지리공간정보가 적용된 멀티 기능 기반의 수치지도 시스템
KR101220271B1 (ko) * 2012-07-05 2013-01-10 대한항업(주) 지피에스 기반 실사 지상물의 게시를 위한 수치지도 제작 시스템
KR101273416B1 (ko) * 2012-07-25 2013-06-11 주식회사 동운 좌표정보 및 지형정보 합성을 통한 정밀 수치지도 제작 시스템
KR101217854B1 (ko) * 2012-09-14 2013-01-02 (주)아세아항측 정밀 디에스엠 및 디티엠 정보와 지상 기준점 정보의 정밀해석을 통한 수치지도 높이오차 확인시스템
JP2016537365A (ja) 2013-11-15 2016-12-01 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用
TWI796250B (zh) * 2015-12-17 2023-03-11 美商亞闊股份有限公司 經取代之 5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
ATE99281T1 (de) 1988-10-13 1994-01-15 Sandoz Ag Verfahren zur herstellung von 7-substituierten hept-6-en- und heptansaeuren und derivaten davon.
US5189164A (en) * 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
FR2655047A1 (fr) * 1989-11-24 1991-05-31 Pf Medicament Derives d'etoposide, leur preparation et leur application comme intermediaires de synthese.
EP0463553A1 (en) * 1990-06-29 1992-01-02 Biochemie Gesellschaft M.B.H. Cephalosporin derivative
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
JPH1067795A (ja) * 1996-03-01 1998-03-10 Takeda Chem Ind Ltd エリスロマイシン誘導体の製造法
ES2194202T3 (es) * 1996-06-24 2003-11-16 Novartis Ag Compuestos polimorfos.
HRP980037B1 (en) * 1997-01-27 2002-04-30 Warner Lambert Co Method of making (1s, 4r)-1-azabicyclo/2.2.1/heptan-3-one and (1r, 4s), 1-azabicyclo/2.2.1/heptan-3-one
EP1163203A1 (en) 1999-03-08 2001-12-19 Merck & Co., Inc. Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
JP4130078B2 (ja) * 1999-06-03 2008-08-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 カルバペネム誘導体結晶と注射製剤
ATE302756T1 (de) * 2000-10-31 2005-09-15 Ciba Sc Holding Ag Kristalline formen von fluvastatin sodium
US7317123B2 (en) 2001-07-06 2008-01-08 Teva Pharmaceutical Industries, Ltd Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation
CA2454072A1 (en) * 2001-08-03 2003-02-20 Paul Adriaan Van Der Schaaf Crystalline forms of fluvastatin sodium
ES2315510T3 (es) * 2002-06-13 2009-04-01 Novartis Ag Sales de calcio de estatinas derivadas del indol.
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
PT1638937E (pt) 2003-06-18 2009-01-27 Teva Pharma Forma xiv cristalina de fluvastatina sódica, processos para a sua preparação, composições que a contêm e métodos de utilização
WO2005037787A1 (en) * 2003-10-16 2005-04-28 Ciba Specialty Chemicals Holding Inc. Crystalline form of fluvastatin sodium
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
WO2006030304A2 (en) 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
JP2008515878A (ja) 2004-10-05 2008-05-15 バイオコン・リミテッド アモルファス型フルバスタチンナトリウムの製造方法
WO2006109147A1 (en) 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
US7432980B2 (en) * 2005-08-05 2008-10-07 Terawins, Inc. Method for reducing analog PLL jitter in video application

Also Published As

Publication number Publication date
EP1719760A3 (en) 2007-03-21
EP1752448A2 (en) 2007-02-14
EP1790635A2 (en) 2007-05-30
EP1638937A2 (en) 2006-03-29
CA2529859A1 (en) 2004-12-29
EP1719759A3 (en) 2007-03-21
MXPA05013895A (es) 2006-03-09
KR20060024428A (ko) 2006-03-16
ES2317012T3 (es) 2009-04-16
CA2610635A1 (en) 2004-12-29
CA2529820A1 (en) 2004-12-29
IL172514A0 (en) 2006-04-10
EP1790634A2 (en) 2007-05-30
KR20060024426A (ko) 2006-03-16
CA2613013A1 (en) 2004-12-29
KR20070092994A (ko) 2007-09-14
WO2004113292B1 (en) 2005-11-10
CN1849304A (zh) 2006-10-18
US20050032884A1 (en) 2005-02-10
JP4037898B2 (ja) 2008-01-23
EP1719759A2 (en) 2006-11-08
DE602004018494D1 (de) 2009-01-29
US7687642B2 (en) 2010-03-30
EP1790635A3 (en) 2007-06-13
EP1719760A2 (en) 2006-11-08
EP1638937B1 (en) 2008-12-17
WO2004113292A2 (en) 2004-12-29
CA2610633A1 (en) 2004-12-29
JP2007302693A (ja) 2007-11-22
EP1752448A3 (en) 2007-03-14
US20090118518A1 (en) 2009-05-07
WO2004113292A3 (en) 2005-10-20
US20080146817A1 (en) 2008-06-19
KR20070094805A (ko) 2007-09-21
EP1790634A3 (en) 2007-06-13
ATE417827T1 (de) 2009-01-15
WO2004113291A3 (en) 2005-04-14
US20090209611A1 (en) 2009-08-20
US7414140B2 (en) 2008-08-19
MXPA05013896A (es) 2006-03-09
EP1726583A3 (en) 2007-05-09
WO2004113291A2 (en) 2004-12-29
JP2007524619A (ja) 2007-08-30
EP1636184A2 (en) 2006-03-22
EP1726583A2 (en) 2006-11-29
JP2007525469A (ja) 2007-09-06
KR20070092995A (ko) 2007-09-14
KR20070092993A (ko) 2007-09-14
IL172512A0 (en) 2006-04-10
EP1780200A1 (en) 2007-05-02
CA2613021A1 (en) 2004-12-29
PT1638937E (pt) 2009-01-27

Similar Documents

Publication Publication Date Title
IL172512A0 (en) Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
EP1896373A4 (en) ARTIFICIAL MARBLE WITH QUARTZ EFFECT USING TRANSPARENT BUILDING BLOCKS AND MANUFACTURING METHOD THEREFOR
HK1085380A1 (en) Immunogenic composition
HK1091814A1 (en) Aminocyclohexyl ether compounds and uses thereof
EP1467758A4 (en) PREPARATION OF IMMUNOCONJUGATES
IL169879A0 (en) Process for preparing pyrrolotriazine derivatives
EP1917224A4 (en) TRANSPARENT CHIPS INCLUDING ART MARGIN USING COEXTRUSION AND METHOD OF MANUFACTURING THEREOF
AU2003290415A1 (en) Herbal oro-dental care composition and process for preparing the same
EP1670894B8 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
EP1661573A4 (en) OPHTHALMIC COMPOSITION
EP1647273A4 (en) OPHTHALMIC COMPOSITION
IL164901A (en) Process for preparing optically active beta-aminoketones
IL183438A0 (en) Substituted indoles, compositions containing them, method for the production thereof and their use
GB0513196D0 (en) Bioreactors for well treatment
GR1003901B (el) Οριζοντιο παλμικο ελαιοραβδιστικο τυπου ταφ ή γαμα
IL150958A0 (en) Compositions containing plant tissues and process for preparing the compositions
AUPS046002A0 (en) Hallmarking process for pearls
AU2003903282A0 (en) The baby pot
AU2003267747A1 (en) Sterile gelling agents
GB0315768D0 (en) Immunogenic composition
GB0315752D0 (en) Immunogenic composition
GB0315762D0 (en) Immunogenic composition
GB0315785D0 (en) Immunogenic composition
GB0315780D0 (en) Immunogenic composition
GB0315778D0 (en) Immunogenic composition